{"status":"ok","message-type":"work-list","message-version":"1.0.0","message":{"facets":{},"total-results":319,"items":[{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:53:53Z","timestamp":1791881633991,"version":"4.3.4"},"description":"Drug","reference-count":0,"publisher":"Royal Pharmaceutical Society","content-domain":{"domain":[],"crossmark-restriction":false},"DOI":"10.18578\/bnf.608179422","type":"component","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T03:29:55Z","timestamp":1667878195000},"source":"Crossref","is-referenced-by-count":0,"title":["rimegepant"],"prefix":"10.18578","member":"162","deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:29:13Z","timestamp":1791880153000},"score":22.609962,"resource":{"primary":{"URL":"https:\/\/www.medicinescomplete.com\/#\/content\/bnf\/_608179422"}},"issued":{"date-parts":[[null]]},"references-count":0,"URL":"https:\/\/doi.org\/10.18578\/bnf.608179422","relation":{"is-component-of":[{"id-type":"doi","id":"10.18578\/BNF.147942626","asserted-by":"object"}]}},{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T04:14:09Z","timestamp":1726719249879},"posted":{"date-parts":[[2024,9,18]]},"reference-count":0,"publisher":"SMW Supporting Association","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"DOI":"10.57187\/preprint.9","type":"posted-content","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T10:18:40Z","timestamp":1726654720000},"source":"Crossref","is-referenced-by-count":0,"title":["Treating Meni\u00e8re\u2019s disease with rimegepant"],"prefix":"10.57187","author":[{"given":"Stefan","family":"Hegemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Schell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36756","deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T10:18:41Z","timestamp":1726654721000},"score":17.448898,"resource":{"primary":{"URL":"https:\/\/www.swissmedpreprints.pub\/index.php\/preprints\/preprint\/view\/9\/version\/9"}},"issued":{"date-parts":[[2024,9,18]]},"references-count":0,"URL":"https:\/\/doi.org\/10.57187\/preprint.9","published":{"date-parts":[[2024,9,18]]},"subtype":"preprint"},{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:39:05Z","timestamp":1772131145373,"version":"3.50.1"},"description":"Supplemental Information for 10.1021\/acs.oprd.1c00376","reference-count":0,"publisher":"American Chemical Society (ACS)","content-domain":{"domain":[],"crossmark-restriction":false},"DOI":"10.1021\/acs.oprd.1c00376.s001","type":"component","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T08:45:43Z","timestamp":1642668343000},"source":"Crossref","is-referenced-by-count":0,"title":["Engineering a Transaminase for the Efficient Synthesis of a Key Intermediate for Rimegepant"],"prefix":"10.1021","member":"316","deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T08:45:43Z","timestamp":1642668343000},"score":17.334713,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/suppl\/10.1021\/acs.oprd.1c00376\/suppl_file\/op1c00376_si_001.pdf"}},"issued":{"date-parts":[[null]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1021\/acs.oprd.1c00376.s001","relation":{"is-component-of":[{"id-type":"doi","id":"10.1021\/acs.oprd.1c00376","asserted-by":"object"}]}},{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:51:47Z","timestamp":1760403107414,"version":"build-2065373602"},"reference-count":0,"publisher":"International Society of Pharmacometrics","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"DOI":"10.70534\/bjll7224","type":"proceedings-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T09:45:56Z","timestamp":1739871956000},"source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetic modeling to support dose selection of rimegepant in pediatrics"],"prefix":"10.70534","author":[{"given":"Chay Ngee","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Comisar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajinder","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijeet","family":"Jakate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"51309","published-online":{"date-parts":[[2024]]},"event":{"name":"American Conference of Pharmacometrics"},"container-title":["Population pharmacokinetic modeling to support dose selection of rimegepant in pediatrics"],"link":[{"URL":"https:\/\/scienceopen.com\/hosted-document?doi=10.70534\/BJLL7224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:50:40Z","timestamp":1760367040000},"score":17.18086,"resource":{"primary":{"URL":"https:\/\/scienceopen.com\/hosted-document?doi=10.70534\/BJLL7224"}},"issued":{"date-parts":[[2024]]},"references-count":0,"URL":"https:\/\/doi.org\/10.70534\/bjll7224","published":{"date-parts":[[2024]]}},{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T16:45:38Z","timestamp":1748969138696,"version":"3.41.0"},"reference-count":0,"publisher":"Geneesmiddelenbulletin Foundation","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2022]]},"DOI":"10.35351\/gebu.nl.2022.8.15","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T09:36:02Z","timestamp":1664184962000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Nieuw geneesmiddel: rimegepant bij migraineaanvallen"],"prefix":"10.35351","volume":"65-68","author":[{"given":"EP","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"19973","container-title":["Ge-Bu"],"language":"nl","deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T09:36:03Z","timestamp":1664184963000},"score":17.120228,"resource":{"primary":{"URL":"https:\/\/www.ge-bu.nl\/artikel\/nieuw-geneesmiddel-rimegepant-bij-migraineaanvallen?utm_source=crossref&utm_medium=referral&utm_campaign=nieuw-geneesmiddel-rimegepant-bij-migraineaanvallen"}},"issued":{"date-parts":[[2022]]},"references-count":0,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.35351\/gebu.nl.2022.8.15","ISSN":["2589-1782"],"issn-type":[{"type":"print","value":"2589-1782"}],"published":{"date-parts":[[2022]]}},{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:14:59Z","timestamp":1789805699157,"version":"4.0.1"},"reference-count":1,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reactions Weekly"],"DOI":"10.1007\/s40278-026-98189-5","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:53:04Z","timestamp":1789804384000},"page":"212-212","source":"Crossref","is-referenced-by-count":0,"title":["Rimegepant"],"prefix":"10.1007","volume":"2128","member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"98189_CR1","doi-asserted-by":"crossref","unstructured":"Hegemann SCA, et al. Treating Meni&#232;re&#x27;s disease with rimegepant. Swiss Medical Weekly 155: 4147, Feb 2025. Available from: URL: \nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/39981723","DOI":"10.57187\/s.4147"}],"container-title":["Reactions Weekly"],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-026-98189-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40278-026-98189-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-026-98189-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:53:05Z","timestamp":1789804385000},"score":16.919739,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40278-026-98189-5"}},"subtitle":["Allergic reaction: case report"],"issued":{"date-parts":[[2026,9,19]]},"references-count":1,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["98189"],"URL":"https:\/\/doi.org\/10.1007\/s40278-026-98189-5","ISSN":["1179-2051"],"issn-type":[{"value":"1179-2051","type":"electronic"}],"published":{"date-parts":[[2026,9,19]]}},{"indexed":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T07:27:21Z","timestamp":1746516441293},"reference-count":6,"publisher":"Infomed-Verlags AG","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["pk"],"published-print":{"date-parts":[[2024,2,2]]},"abstract":"<jats:p>N\/A<\/jats:p>","DOI":"10.37667\/pk.2023.1274","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T20:24:22Z","timestamp":1720729462000},"source":"Crossref","is-referenced-by-count":1,"title":["Rimegepant"],"prefix":"10.37667","volume":"45","author":[{"given":"Etzel","family":"Gysling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"24093","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Croop R, Ivans A, Anderson MS, et al. A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults. Cephalalgia Reports. 2021 April 29; 4. doi:10.1177\/25158163211007922","DOI":"10.1177\/25158163211007922"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Blair HA. Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine. CNS Drugs. 2023 Mar;37(3):255-265. doi: 10.1007\/s40263-023-00988-8. Epub 2023 Feb 4. Erratum in: CNS Drugs. 2023 Jul;37(7):661. PMID: 36739335; PMCID: PMC10299922.","DOI":"10.1007\/s40263-023-00988-8"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019 Aug 31;394(10200):737-745. doi: 10.1016\/S0140-6736(19)31606-X. Epub 2019 Jul 13. PMID: 31311674.","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014 Feb;34(2):114-25. doi: 10.1177\/0333102413500727. Epub 2013 Aug 21. PMID: 23965396.","DOI":"10.1177\/0333102413500727"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021 Jan 2;397(10268):51-60. doi: 10.1016\/S0140-6736(20)32544-7. Epub 2020 Dec 15. PMID: 33338437.","DOI":"10.1016\/S0140-6736(20)32544-7"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Schwedt TJ, Myers Oakes TM, Martinez JM, Vargas BB, Pandey H, Pearlman EM, Richardson DR, Varnado OJ, Cobas Meyer M, Goadsby PJ. Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial. Neurol Ther. 2024 Feb;13(1):85-105. doi: 10.1007\/s40120-023-00562-w. Epub 2023 Nov 10. PMID: 37948006; PMCID: PMC10787669.","DOI":"10.1007\/s40120-023-00562-w"}],"container-title":["pharma-kritik"],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T20:24:26Z","timestamp":1720729466000},"score":16.876575,"resource":{"primary":{"URL":"https:\/\/www.infomed.ch\/pk_template.php?pkid=1274"}},"issued":{"date-parts":[[2024,2,2]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,2,2]]}},"URL":"https:\/\/doi.org\/10.37667\/pk.2023.1274","ISSN":["1010-5409"],"issn-type":[{"value":"1010-5409","type":"print"}],"published":{"date-parts":[[2024,2,2]]}},{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T03:25:23Z","timestamp":1787196323348,"version":"build-2736575974"},"reference-count":0,"publisher":"BMJ Publishing Group Ltd","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1136\/jnnp-2025-abn.154","type":"proceedings-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:25:50Z","timestamp":1765704350000},"page":"A47.2-A47","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["154\u2005Treatment outcomes in people with migraine receiving rimegepant or triptans: a real-world descriptive analysis"],"prefix":"10.1136","author":[{"given":"Abraham","family":"Lucy","sequence":"first","affiliation":[{"name":"Pfizer RandD UK Ltd., Tadworth"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brown","family":"Joshua","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hygge-Blakeman","family":"Karin","sequence":"additional","affiliation":[{"name":"Pfizer, AB., Stockholm"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Feng","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson","family":"James","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitton","family":"William","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barlow","family":"Sophie","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hancock","family":"Lucy","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,26]]},"event":{"name":"ABN Annual Meeting Abstracts 2025"},"container-title":["154\u2005Treatment outcomes in people with migraine receiving rimegepant or triptans: a real-world descriptive analysis"],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2025-ABN.154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T03:02:08Z","timestamp":1787194928000},"score":16.781174,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2025-ABN.154"}},"issued":{"date-parts":[[2025,11,26]]},"references-count":0,"alternative-id":["10.1136\/jnnp-2025-ABN.154"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2025-abn.154","published":{"date-parts":[[2025,11,26]]}},{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T11:18:16Z","timestamp":1648639096815},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"13","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2020,6,23]]},"DOI":"10.1093\/ajhp\/zxaa109","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T09:05:20Z","timestamp":1592903120000},"page":"999-1000","source":"Crossref","is-referenced-by-count":0,"title":["Rimegepant Sulfate"],"prefix":"10.1093","volume":"77","member":"286","published-online":{"date-parts":[[2020,6,23]]},"container-title":["American Journal of Health-System Pharmacy"],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/13\/999\/33414716\/zxaa109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/13\/999\/33414716\/zxaa109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T09:05:20Z","timestamp":1592903120000},"score":16.709328,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/77\/13\/999\/5860756"}},"issued":{"date-parts":[[2020,6,23]]},"references-count":0,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2020,6,23]]},"published-print":{"date-parts":[[2020,6,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaa109","ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"published-other":{"date-parts":[[2020,7,1]]},"published":{"date-parts":[[2020,6,23]]}},{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T03:25:43Z","timestamp":1787196343718,"version":"build-2736575974"},"reference-count":0,"publisher":"BMJ Publishing Group Ltd","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1136\/jnnp-2025-abn.159","type":"proceedings-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:25:50Z","timestamp":1765704350000},"page":"A49.1-A49","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["159\u2005Long-term safety and discontinuation for rimegepant versus triptans: a matching-adjusted indirect comparison"],"prefix":"10.1136","clinical-trial-number":[{"clinical-trial-number":"nct03266588","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Powell","family":"Lauren","sequence":"first","affiliation":[{"name":"Broadstreet HEOR, Vancouver"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"de Br\u00fan","family":"Ciara","sequence":"additional","affiliation":[{"name":"Broadstreet HEOR, Vancouver"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogula","family":"Basia","sequence":"additional","affiliation":[{"name":"Broadstreet HEOR, Vancouver"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenkins","family":"Aaron","sequence":"additional","affiliation":[{"name":"Pfizer Ltd, Tadworth"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atkinson","family":"Jo","sequence":"additional","affiliation":[{"name":"Pfizer Ltd, Tadworth"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Lucy","sequence":"additional","affiliation":[{"name":"Pfizer Ltd, Tadworth"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,26]]},"event":{"name":"ABN Annual Meeting Abstracts 2025"},"container-title":["159\u2005Long-term safety and discontinuation for rimegepant versus triptans: a matching-adjusted indirect comparison"],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2025-ABN.159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T03:02:40Z","timestamp":1787194960000},"score":16.663544,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2025-ABN.159"}},"issued":{"date-parts":[[2025,11,26]]},"references-count":0,"alternative-id":["10.1136\/jnnp-2025-ABN.159"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2025-abn.159","published":{"date-parts":[[2025,11,26]]}},{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:15:54Z","timestamp":1775229354953,"version":"3.50.1"},"reference-count":0,"publisher":"Therapeutic Guidelines Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aust Prescr"],"DOI":"10.18773\/austprescr.2024.029","type":"journal-article","created":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T20:54:37Z","timestamp":1724014477000},"page":"134-135","source":"Crossref","is-referenced-by-count":0,"title":["New Drug: Rimegepant for migraine"],"prefix":"10.18773","volume":"47","member":"39051","published-online":{"date-parts":[[2024,8,20]]},"container-title":["Australian Prescriber"],"link":[{"URL":"https:\/\/australianprescriber.tg.org.au\/articles\/rimegepant-for-migraine.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:37:26Z","timestamp":1775227046000},"score":16.563234,"resource":{"primary":{"URL":"https:\/\/australianprescriber.tg.org.au\/articles\/rimegepant-for-migraine.html"}},"issued":{"date-parts":[[2024,8,20]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8,20]]}},"URL":"https:\/\/doi.org\/10.18773\/austprescr.2024.029","ISSN":["1839-3942"],"issn-type":[{"value":"1839-3942","type":"electronic"}],"published":{"date-parts":[[2024,8,20]]}},{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:45:30Z","timestamp":1778715930936,"version":"3.51.4"},"reference-count":2,"publisher":"BMJ","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj.p2104","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T13:52:28Z","timestamp":1694699548000},"page":"p2104","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["NICE recommends rimegepant for treating acute migraine in adults"],"prefix":"10.1136","author":[{"given":"Gareth","family":"Iacobucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"2023091412450601000_382.sep14_2.p2104.1","unstructured":"National Institute for Health and Care Excellence. Rimegepant for treating migraine: final appraisal document. Sep 2023. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10839\/documents"},{"key":"2023091412450601000_382.sep14_2.p2104.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p1249"}],"container-title":["BMJ"],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.p2104","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.p2104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:45:13Z","timestamp":1694720713000},"score":16.45626,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.p2104"}},"issued":{"date-parts":[[2023,9,14]]},"references-count":2,"alternative-id":["10.1136\/bmj.p2104"],"URL":"https:\/\/doi.org\/10.1136\/bmj.p2104","ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"published":{"date-parts":[[2023,9,14]]}},{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T16:45:37Z","timestamp":1748969137683,"version":"3.41.0"},"reference-count":0,"publisher":"Geneesmiddelenbulletin Foundation","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2022]]},"DOI":"10.35351\/gebu.2022.8.15","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T11:49:12Z","timestamp":1661773752000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["New drug: rimegepant for migraine attacks"],"prefix":"10.35351","volume":"65-68","author":[{"given":"EP","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"19973","container-title":["Ge-Bu"],"language":"nl","deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T19:32:48Z","timestamp":1747251168000},"score":16.438766,"resource":{"primary":{"URL":"https:\/\/www.ge-bu.nl\/en\/artikel\/nieuw-geneesmiddel-rimegepant-bij-migraineaanvallen"}},"issued":{"date-parts":[[2022]]},"references-count":0,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.35351\/gebu.2022.8.15","ISSN":["2589-1782"],"issn-type":[{"type":"print","value":"2589-1782"}],"published":{"date-parts":[[2022]]}},{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:38:54Z","timestamp":1792737534663,"version":"4.5.0"},"reference-count":8,"publisher":"Journal of Biomedical Research","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Biomed Res"],"published-print":{"date-parts":[[2026]]},"DOI":"10.7555\/jbr.40.20260389","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:03:07Z","timestamp":1792735387000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Role of lateral septal nucleus involvement in rimegepant treatment of migraine Running title: Lateral septal nucleus in rimegepant migraine analgesia"],"prefix":"10.7555","volume":"40","author":[{"given":"Chenyang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4380","reference":[{"key":"10.7555\/JBR.40.20260389.swyxyjzzywb.1","doi-asserted-by":"publisher","unstructured":"Ashina M. Migraine[J]. <i>N Engl J Med<\/i>, 2020, 383(19): 1866\u20131876.","DOI":"10.1056\/NEJMra1915327"},{"key":"10.7555\/JBR.40.20260389.swyxyjzzywb.2","doi-asserted-by":"publisher","unstructured":"Schulte LH, Mehnert J, May A. Longitudinal neuroimaging over 30 days: Temporal characteristics of migraine[J]. <i>Ann Neurol<\/i>, 2020, 87(4): 646\u2013651.","DOI":"10.1002\/ana.25697"},{"key":"10.7555\/JBR.40.20260389.swyxyjzzywb.3","doi-asserted-by":"publisher","unstructured":"He W, Long T, Pan Q, et al. Microglial NLRP3 inflammasome activation mediates IL-1\u03b2 release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model[J]. <i>J Neuroinflammation<\/i>, 2019, 16(1): 78.","DOI":"10.1186\/s12974-019-1459-7"},{"key":"10.7555\/JBR.40.20260389.swyxyjzzywb.4","doi-asserted-by":"publisher","unstructured":"Dorsey S, Ijaz A, Ahmed F. Migraine: Symptoms, types, pathophysiology and diagnosis[J]. <i>BJA Educ<\/i>, 2025, 25(11): 439\u2013445.","DOI":"10.1016\/j.bjae.2025.07.004"},{"key":"10.7555\/JBR.40.20260389.swyxyjzzywb.5","doi-asserted-by":"publisher","unstructured":"Christensen CE, Younis S, Deen M, et al. Migraine induction with calcitonin gene-related peptide in patients from erenumab trials[J]. <i>J Headache Pain<\/i>, 2018, 19(1): 105.","DOI":"10.1186\/s10194-018-0927-2"},{"key":"10.7555\/JBR.40.20260389.swyxyjzzywb.6","doi-asserted-by":"publisher","unstructured":"Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine[J]. <i>N Engl J Med<\/i>, 2019, 381(2): 142\u2013149.","DOI":"10.1056\/NEJMoa1811090"},{"key":"10.7555\/JBR.40.20260389.swyxyjzzywb.7","doi-asserted-by":"publisher","unstructured":"Sheehan TP, Chambers RA, Russell DS. Regulation of affect by the lateral septum: Implications for neuropsychiatry[J]. <i>Brain Res Brain Res Rev<\/i>, 2004, 46(1): 71\u2013117.","DOI":"10.1016\/j.brainresrev.2004.04.009"},{"key":"10.7555\/JBR.40.20260389.swyxyjzzywb.8","doi-asserted-by":"publisher","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: A disorder of sensory processing[J]. <i>Physiol Rev<\/i>, 2017, 97(2): 553\u2013622.","DOI":"10.1152\/physrev.00034.2015"}],"container-title":["Journal of Biomedical Research"],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:03:07Z","timestamp":1792735387000},"score":16.255238,"resource":{"primary":{"URL":"http:\/\/www.jbr-pub.org.cn\/article\/doi\/10.7555\/JBR.40.20260389"}},"issued":{"date-parts":[[2026]]},"references-count":8,"alternative-id":["JBR-2026-0389"],"URL":"https:\/\/doi.org\/10.7555\/jbr.40.20260389","ISSN":["1674-8301","1674-8301"],"issn-type":[{"value":"1674-8301","type":"print"},{"value":"1674-8301","type":"electronic"}],"published":{"date-parts":[[2026]]}},{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T03:25:30Z","timestamp":1787196330886,"version":"build-2736575974"},"reference-count":0,"publisher":"BMJ Publishing Group Ltd","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1136\/jnnp-2025-abn.155","type":"proceedings-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:25:50Z","timestamp":1765704350000},"page":"A47.3-A47","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["155\u2005Cardiovascular and cerebrovascular events during treatment of migraine with rimegepant: analysis of post-authorization safety data"],"prefix":"10.1136","author":[{"given":"Chan","family":"Anthony","sequence":"first","affiliation":[{"name":"Pfizer Healthcare Ireland, Dublin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Founraine Robert","family":"J","sequence":"additional","affiliation":[{"name":"Pfizer RandD, Groton"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawinski","family":"Robert","sequence":"additional","affiliation":[{"name":"Pfizer Ltd., Tadworth"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pixton","family":"Glenn","sequence":"additional","affiliation":[{"name":"Pfizer RandD, Groton"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Straghan","family":"Esther","sequence":"additional","affiliation":[{"name":"Pfizer Ltd., Tadworth"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,26]]},"event":{"name":"ABN Annual Meeting Abstracts 2025"},"container-title":["155\u2005Cardiovascular and cerebrovascular events during treatment of migraine with rimegepant: analysis of post-authorization safety data"],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2025-ABN.155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T03:02:28Z","timestamp":1787194948000},"score":16.105612,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2025-ABN.155"}},"issued":{"date-parts":[[2025,11,26]]},"references-count":0,"alternative-id":["10.1136\/jnnp-2025-ABN.155"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2025-abn.155","published":{"date-parts":[[2025,11,26]]}},{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:00:18Z","timestamp":1780102818721,"version":"3.54.0"},"reference-count":0,"publisher":"Portico","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"DOI":"10.1358\/dot.2020.56.12.3211624","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T04:32:32Z","timestamp":1607401952000},"page":"769","source":"Crossref","is-referenced-by-count":16,"title":["Rimegepant for the treatment of migraine"],"prefix":"10.3730","volume":"56","author":[{"family":"Negro, A.","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Martelletti, P.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1320","published-online":{"date-parts":[[2020]]},"container-title":["Drugs of Today"],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T13:03:53Z","timestamp":1685451833000},"score":15.970684,"resource":{"primary":{"URL":"http:\/\/access.portico.org\/stable?au=pjbf7dcqj2v"}},"issued":{"date-parts":[[2020]]},"references-count":0,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1358\/dot.2020.56.12.3211624","ISSN":["1699-4019"],"issn-type":[{"value":"1699-4019","type":"print"}],"published":{"date-parts":[[2020]]}},{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:19:15Z","timestamp":1747153155312,"version":"3.40.5"},"publisher-location":"Cham","reference-count":19,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030953331"},{"type":"electronic","value":"9783030953348"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-3-030-95334-8_5","type":"book-chapter","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T20:02:35Z","timestamp":1651003355000},"page":"51-66","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rimegepant"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3590-298X","authenticated-orcid":false,"given":"Andrea","family":"Negro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"5_CR1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/14656566.2020.1862793","volume":"22","author":"A Negro","year":"2021","unstructured":"Negro A, Martelletti P. Novel synthetic treatment options for migraine. Expert Opin Pharmacother. 2021;22:907\u201322.","journal-title":"Expert Opin Pharmacother"},{"key":"5_CR2","unstructured":"Biohaven\u2019s NURTEC\u00ae ODT (rimegepant) receives FDA approval for the acute treatment of migraine in adults. Biohaven Pharmaceuticals, 27 Feb 2020. Available from: https:\/\/www.biohavenpharma.com\/investors\/news-events\/press-releases\/02-27-2020. Accessed 20 Sept 2021."},{"key":"5_CR3","unstructured":"FDA approves Biohaven\u2019s NURTEC\u00ae ODT (rimegepant) for prevention: now the first and only migraine medication for both acute and preventive treatment. Biohaven Pharmaceuticals, 27 May 2021. Available from: https:\/\/www.biohavenpharma.com\/investors\/news-events\/press-releases\/05-27-2021. Accessed 20 Sept 2021."},{"key":"5_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10194-011-0388-3","volume":"12","author":"A Negro","year":"2011","unstructured":"Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain. 2011;12:593\u2013601.","journal-title":"J Headache Pain"},{"key":"5_CR5","unstructured":"Rimegepant. DrugBank. https:\/\/go.drugbank.com\/drugs\/DB12457. Accessed 20 Sept 2021."},{"issue":"23","key":"5_CR6","doi-asserted-by":"publisher","first-page":"10644","DOI":"10.1021\/jm3013147","volume":"55","author":"G Luo","year":"2012","unstructured":"Luo G, Chen L, Conway CM, Denton R, Keavy D, Signor L, et al. Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine. J Med Chem. 2012;55(23):10644\u201351.","journal-title":"J Med Chem"},{"key":"5_CR7","unstructured":"Nurtec ODT (rimegepant) orally disintegrating tablets [highlights of prescribing information]. Food and Drug Administration (FDA). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212728s000lbl.pdf. Accessed 20 Sept 2021."},{"key":"5_CR8","unstructured":"Croop R, Ivans A, Stock D, et al. A phase 1 study to evaluate the bioequivalence of oral tablet and orally dissolving tablet formulations of rimegepant, a small molecule CGRP receptor antagonist. 17th Migraine Trust Intl Symp (MTIS) (Sep 6\u20139, London) 2018, Abst MTIS2018\u2013170."},{"key":"5_CR9","unstructured":"Study to evaluate the PK of BMS-927711 in patient with migraine during acute migraine and non-migraine condition (NCT01445067). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01445067. Accessed 20 Sept 2021."},{"issue":"2","key":"5_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0333102413500727","volume":"34","author":"R Marcus","year":"2014","unstructured":"Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34(2):114\u201325.","journal-title":"Cephalalgia"},{"key":"5_CR11","unstructured":"Safety and efficacy study in adult subjects with acute migraines (NCT03235479). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03235479. Accessed 20 Sept 2021."},{"key":"5_CR12","first-page":"1336","volume":"58","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Conway CM, Stock EG, Stock D, Morris BA, McCormack T, et al. Efficacy, safety, and tolerability of rimegepant 75 mg, an oral CGRP receptor antagonist, for the acute treatment of migraine: results from a double-blind, randomized, placebo-controlled trial, study 301. Headache. 2018;58:1336\u20137. (Abst PS123LB)","journal-title":"Headache"},{"issue":"2","key":"5_CR13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142\u20139.","journal-title":"N Engl J Med"},{"issue":"10200","key":"5_CR14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737\u201345.","journal-title":"Lancet"},{"issue":"10268","key":"5_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51\u201360.","journal-title":"Lancet"},{"key":"5_CR16","unstructured":"Open label safety study in acute treatment of migraine (NCT03266588). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03266588. Accessed 20 Sept 2021."},{"key":"5_CR17","volume-title":"American Headache Society 61st Annual Scientific Meeting; July 11\u201314","author":"R Lipton","year":"2019","unstructured":"Lipton R, Berman G, Kudrow D, Mullin K, Thiry A, Lovegren M, et al. Long-term, open-label safety study of rimegepant 75 mg for the treatment of migraine (Study 201): interim analysis of safety and exploratory efficacy. In:  American Headache Society 61st Annual Scientific Meeting; July 11\u201314. Philadelphia, PA: AHS; 2019."},{"key":"5_CR18","unstructured":"An open-label, intermediate size, expanded access study of BHV-3000 in the acute treatment of migraine (NCT03934086). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03934086. Accessed 20 Sept 2021."},{"key":"5_CR19","doi-asserted-by":"crossref","unstructured":"Negro A, Delaruelle Z, Ivanova TA, Khan S, Ornello R, Raffaelli B, et al., on behalf of the European Headache Federation School of Advanced Studies (EHF-SAS). Headache and pregnancy: a systematic review. J Headache Pain. 2017;18(1):106.","DOI":"10.1186\/s10194-017-0816-0"}],"container-title":["Headache","Novel Synthetic Drugs in Migraine"],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-95334-8_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T20:07:11Z","timestamp":1651003631000},"score":15.961279,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-95334-8_5"}},"issued":{"date-parts":[[2022]]},"ISBN":["9783030953331","9783030953348"],"references-count":19,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-95334-8_5","ISSN":["2197-652X","2197-6538"],"issn-type":[{"type":"print","value":"2197-652X"},{"type":"electronic","value":"2197-6538"}],"published":{"date-parts":[[2022]]},"assertion":[{"value":"27 April 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]},{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:18:33Z","timestamp":1790626713360,"version":"4.1.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"10268","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/s0140-6736(20)32624-6","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T22:35:05Z","timestamp":1608158105000},"page":"4-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Oral rimegepant for migraine prevention"],"prefix":"10.1016","volume":"397","author":[{"given":"Lars","family":"Edvinsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(20)32624-6_bib1","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(19)32504-8","article-title":"Targeting calcitonin gene-related peptide: a new era in migraine therapy","volume":"394","author":"Charles","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(20)32624-6_bib2","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial","author":"Croop","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(20)32624-6_bib3","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102420941839","article-title":"Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults","volume":"40","author":"Diener","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/S0140-6736(20)32624-6_bib4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/0333102418758283","article-title":"Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults","volume":"38","author":"Tassorelli","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/S0140-6736(20)32624-6_bib5","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention","volume":"83","author":"Ho","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(20)32624-6_bib6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","article-title":"Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial","volume":"19","author":"Goadsby","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/S0140-6736(20)32624-6_bib7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0333102419884943","article-title":"Characterization of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries","volume":"40","author":"Rubio-Beltran","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/S0140-6736(20)32624-6_bib8","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.25831","article-title":"Anti-migraine calcitonin gene-related peptide receptor antagonists worsen cerebral ischemic outcome in mice","volume":"88","author":"Mulder","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/S0140-6736(20)32624-6_bib9","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","article-title":"Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine","volume":"350","author":"Olesen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(20)32624-6_bib10","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1212\/WNL.0b013e3181b87942","article-title":"Randomized, controlled trial of telcagepant for the acute treatment of migraine","volume":"73","author":"Connor","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(20)32624-6_bib11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial","volume":"394","author":"Croop","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(20)32624-6_bib12","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for treatment of migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N Engl J Med"}],"container-title":["The Lancet"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673620326246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673620326246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T07:38:47Z","timestamp":1718437127000},"score":15.961279,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673620326246"}},"issued":{"date-parts":[[2021,1]]},"references-count":12,"journal-issue":{"issue":"10268","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0140673620326246"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(20)32624-6","ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral rimegepant for migraine prevention","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(20)32624-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(20)32544-7","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]},{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:43:16Z","timestamp":1787665396839,"version":"build-2736575974"},"publisher-location":"Baarn, the Netherlands","reference-count":0,"publisher":"Medicom Medical Publishers","content-domain":{"domain":[],"crossmark-restriction":false},"DOI":"10.55788\/ca4cc343","type":"proceedings-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:53:16Z","timestamp":1736142796000},"source":"Crossref","is-referenced-by-count":0,"title":["Rimegepant reduces migraine symptoms through 1 year of treatment"],"prefix":"10.55788","author":[{"given":"Mihai","family":"Surducan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"57334","published-online":{"date-parts":[[2025,1,6]]},"event":{"name":"18th European Headache Congress","theme":"Neurology","location":"Rotterdam, the Netherlands","acronym":"EHC 2024","start":{"date-parts":[[2024,12,4]]},"end":{"date-parts":[[2024,12,4]]}},"container-title":["Medicom Conference Report EHC 2024"],"link":[{"URL":"https:\/\/conferences.medicom-publishers.com\/?p=42807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:53:20Z","timestamp":1736142800000},"score":15.904129,"resource":{"primary":{"URL":"https:\/\/conferences.medicom-publishers.com\/?p=42807"}},"editor":[{"given":"Rachel","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"proceedings-subject":"Neurology","issued":{"date-parts":[[2025,1,6]]},"references-count":0,"URL":"https:\/\/doi.org\/10.55788\/ca4cc343","published":{"date-parts":[[2025,1,6]]}},{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T03:25:32Z","timestamp":1787196332266,"version":"build-2736575974"},"reference-count":0,"publisher":"BMJ Publishing Group Ltd","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1136\/jnnp-2025-abn.165","type":"proceedings-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:25:50Z","timestamp":1765704350000},"page":"A50.4-A51","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["165\u2005Efficacy and safety of rimegepant for the acute treatment of migraine in Japan"],"prefix":"10.1136","author":[{"given":"Matsumori","family":"Yasuhiko","sequence":"first","affiliation":[{"name":"Sendai Headache and Neurology Clinic, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikeda","family":"Koichi","sequence":"additional","affiliation":[{"name":"Ikeda Neurosurgical Clinic, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kudo","family":"Masako","sequence":"additional","affiliation":[{"name":"Iwate Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishikawa","family":"Tomofumi","sequence":"additional","affiliation":[{"name":"Pfizer RandD, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimatsu","family":"Hiroki","sequence":"additional","affiliation":[{"name":"Pfizer RandD, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiry","family":"Alexandra","sequence":"additional","affiliation":[{"name":"Pfizer, Groton"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Croop","family":"Robert","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals, New Haven"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fullerton","family":"Terence","sequence":"additional","affiliation":[{"name":"Pfizer, Groton"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakai","family":"Fumihiko","sequence":"additional","affiliation":[{"name":"Saitama International Headache Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshima","family":"Takao","sequence":"additional","affiliation":[{"name":"Tominaga Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,26]]},"event":{"name":"ABN Annual Meeting Abstracts 2025"},"container-title":["165\u2005Efficacy and safety of rimegepant for the acute treatment of migraine in Japan"],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2025-ABN.165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T03:02:33Z","timestamp":1787194953000},"score":15.848917,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2025-ABN.165"}},"issued":{"date-parts":[[2025,11,26]]},"references-count":0,"alternative-id":["10.1136\/jnnp-2025-ABN.165"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2025-abn.165","published":{"date-parts":[[2025,11,26]]}}],"items-per-page":20,"query":{"start-index":0,"search-terms":null}}}